Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term

News Hour:

Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting mealtime insulin, improved overall blood sugar and post-meal sugar control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings.

The findings were presented at the 53rd European Association for the Study of Diabetes (EASD) Annual Meeting and showed that Fiasp® maintained the significant improvement in overall blood sugar control that was seen in a shorter-term (26 weeks) study period. The results also reconfirmed the safety profile of Fiasp®, showing comparable overall numbers of severe or blood-sugar confirmed hypoglycemia (low blood sugar levels).

“These results provide reassurance of the meaningful long-term benefits of Fiasp®versus conventional insulin aspart,” said Professor Chantal Mathieu, study investigator, chair of Endocrinology and Professor of Medicine at Katholieke Universiteit Leuven, Belgium.

“Accordingly, for people with diabetes who struggle to control their post-meal sugar levels, Fiasp® might offer a better option to meet their needs.”

After eating, blood sugar levels rise rapidly. In diabetes, the body either cannot bring these high sugar levels down or struggles to do so. Sustained high post-meal sugar levels are associated with an increased risk of cardiovascular disease and other diabetes-related complications, including damage to eyes and kidneys and cancer. High post-meal sugar levels also contribute to inadequate overall blood sugar control.

While mealtime insulins aim to bring post-meal sugar levels down, conventional rapid-acting insulins are not as fast as the speed of the natural physiological insulin response. Due to this slower response, people with diabetes can remain in an elevated post-meal sugar state for an extended period.

“Compared to conventional insulin aspart, Fiasp® is a closer match to the natural physiological insulin response, leading to better long-term blood sugar control,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

“Fiasp® delivers benefits for people with diabetes, helping them to achieve better post-meal and overall blood sugar control.”

Have your say, we value it!

wise people got already engaged

This article is posted by a News Hour Correspondent. For queries, please contact through [email protected]
Scroll Up